Abstract
Objective To evaluate the pharmacoeconomical outcome of anti-ventricular arrhythmia drugs,to provide reference for national selection of anti-ventricular arrhythmia drugs.Methods By searching literatures,collected the information of efficacy and safety of 10 kinds of anti-ventricular arrhythmia drugs; took the top limit of monthly expense as cost and efficiency as effectiveness to do cost-effectiveness analysis and sensitivity analysis.Results The total effective rate of anti-ventricular arrhythmia medicine was 78.71％,and drug adverse reaction rate was 13.97％.The low cost-effectiveness drugs were mexiletine ＜ atenolol ＜ propafenone ＜ amiodarone ＜ sotolol ＜ metoprolol ＜ bisoprolol; the high cost-effectiveness drugs were moracizine ＞ Wenxin grannle ＞ SRYX capsule; the low ADR rate drugs were bisoprolol ＜ SRYX capsule ＜ Wenxin grannle ＜ atenolol ＜ metoprolol; the high ADR rate drugs were sotolol ＞ moracizine ＞ mexiletine ＞ amiodarone ＞ propafenone.Conclusion Atenolol,metoprolol,bisoprolol belong to high efficient,safe and low cost medicine.In the drug economics we encourage to use high efficient,safe and low cost drugs. Key words: Anti-ventricular arrhythmia drugs; Efficacy; Safety; Pharmacoeconomics; Cost-effectiveness analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
